Largest Psychedelic Compound-Based R&D Stocks Continue Downward Trend

The 6 psychedelic compound-based research & development stocks in our munKNEE Psychedelic Drug Stocks Index were down an average of 6% last week and are now down 17.2% so far in August. They are ranked below in descending order as to their performances last week and MTD (month-to-date).

  1. Compass Pathways (CMPS): UP 1.6% last week; down 9.4% MTD
  2. Atai (ATAI): down 6.0% last week; down 23.3% MTD
  3. Mind Medicine (MNMD): down 6.3% last week; down 8.5% MTD
  4. GH Research (GHRS): down 8.3% last week; down 22.5% MTD
    • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine but is better known by its nickname, “The Toad”.
    • Market Capitalization: $567M
    • Stock Price: $10.90
    • Short Interest: 11.1%
  5. Incannex Healthcare (IXHL): down 12.1% last week; down 22.0% MTD
  6. Seelos (SEEL): down 22.2% last week; down 5.8% MTD

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.


The munKNEE Psychedelic Drug Stocks Index was down 6.0% last week and is now down 17.2% MTD.

If you are interested in this category, consider the  AdvisorShares Psychedelic ETF (PSIL), which consists of 23 such stocks (of which the majority have market capitalizations of less than $50M). It was down 5.0% last week and is now down 12.8% MTD.

More By This Author:

5 Largest Canadian Cannabis LPs Up Last Week
Bitcoin’s Recent Plummet And Global Crypto Impacts
The AI Sector Consists Of A Number Of Categories - Check Them Out

Disclosure: None

Visit and register to receive our free Market Intelligence Report newsletter (sample  more

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.